Selective antisense compounds and uses thereof Grant US-11732261-B2 United States of America 22 Aug 2023
Compounds and methods for reducing ATXN3 expression Grant US-11583548-B2 United States of America 21 Feb 2023
Compounds and methods for reducing ATXN3 expression Grant US-11434488-B2 United States of America 06 Sep 2022
Compositions and methods for modulating Ataxin 3 expression Grant US-11293025-B2 United States of America 05 Apr 2022
Selective antisense compounds and uses thereof Grant US-11236335-B2 United States of America 01 Feb 2022
OLIGONUCLEOTIDE PRIMERS FOR THE CHARACTERIZATION OF THE CAG TRACT AND MEASUREMENT OF… Application WO-2021095001-A1 World Intellectual Property Organisation (WIPO) 20 May 2021
COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION Application EP-3538656-A4 European Patent Office 19 Aug 2020
DOUBLE STRANDED RNA AND USES THEREOF Application WO-2020144611-A1 World Intellectual Property Organisation (WIPO) 16 Jul 2020
Compositions and methods for modulating Ataxin 3 expression Application US-10533175-B2 United States of America 14 Jan 2020
Selective antisense compounds and uses thereof Grant US-10202599-B2 United States of America 12 Feb 2019
EXPRESSION VECTOR FOR CHOLESTEROL 24-HYDROLASE IN THERAPY OF POLYGLUTAMINE REPEAT… Application WO-2018138371-A1 World Intellectual Property Organisation (WIPO) 02 Aug 2018
Gapped oligomeric compounds comprising 5′-modified deoxyribonucleosides in the gap and… Grant US-9752142-B2 United States of America 05 Sep 2017
Selective inhibition of polyglutamine protein expression Grant US-9574191-B2 United States of America 21 Feb 2017
COMPOSITIONS AND METHODS FOR MODULATION OF ATXN3 EXPRESSION Application EP-2839008-A4 European Patent Office 02 Dec 2015